An mRNA assay system demonstrates proteasomal-specific degradation contributes to cardiomyopathic phospholamban null mutation.
Alleles
Amino Acid Substitution
Biomarkers
Calcium-Binding Proteins
/ chemistry
Cardiomyopathies
/ diagnosis
Cell Line
Disease Susceptibility
Gene Expression Profiling
Homozygote
Humans
Mutation
Proteasome Endopeptidase Complex
/ metabolism
Protein Biosynthesis
RNA Stability
RNA, Messenger
/ genetics
Disease model
L39X
Modified mRNA
PLN
Journal
Molecular medicine (Cambridge, Mass.)
ISSN: 1528-3658
Titre abrégé: Mol Med
Pays: England
ID NLM: 9501023
Informations de publication
Date de publication:
08 09 2021
08 09 2021
Historique:
received:
28
03
2021
accepted:
24
08
2021
entrez:
9
9
2021
pubmed:
10
9
2021
medline:
21
1
2022
Statut:
epublish
Résumé
The human L39X phospholamban (PLN) cardiomyopathic mutant has previously been reported as a null mutation but the detailed molecular pathways that lead to the complete lack of detectable protein remain to be clarified. Previous studies have shown the implication between an impaired cellular degradation homeostasis and cardiomyopathy development. Therefore, uncovering the underlying mechanism responsible for the lack of PLN protein has important implications in understanding the patient pathology, chronic human calcium dysregulation and aid the development of potential therapeutics. A panel of mutant and wild-type reporter tagged PLN modified mRNA (modRNA) constructs were transfected in human embryonic stem cell-derived cardiomyocytes. Lysosomal and proteasomal chemical inhibitors were used together with cell imaging and protein analysis tools in order to dissect degradation pathways associated with expressed PLN constructs. Transcriptional profiling of the cardiomyocytes transfected by wild-type or L39X mutant PLN modRNA was analysed with bulk RNA sequencing. Our modRNA assay system revealed that transfected L39X mRNA was stable and actively translated in vitro but with only trace amount of protein detectable. Proteasomal inhibition of cardiomyocytes transfected with L39X mutant PLN modRNA showed a fourfold increase in protein expression levels. Additionally, RNA sequencing analysis of protein degradational pathways showed a significant distinct transcriptomic signature between wild-type and L39X mutant PLN modRNA transfected cardiomyocytes. Our results demonstrate that the cardiomyopathic PLN null mutant L39X is rapidly, actively and specifically degraded by proteasomal pathways. Herein, and to the best of our knowledge, we report for the first time the usage of modified mRNAs to screen for and illuminate alternative molecular pathways found in genes associated with inherited cardiomyopathies.
Sections du résumé
BACKGROUND
The human L39X phospholamban (PLN) cardiomyopathic mutant has previously been reported as a null mutation but the detailed molecular pathways that lead to the complete lack of detectable protein remain to be clarified. Previous studies have shown the implication between an impaired cellular degradation homeostasis and cardiomyopathy development. Therefore, uncovering the underlying mechanism responsible for the lack of PLN protein has important implications in understanding the patient pathology, chronic human calcium dysregulation and aid the development of potential therapeutics.
METHODS
A panel of mutant and wild-type reporter tagged PLN modified mRNA (modRNA) constructs were transfected in human embryonic stem cell-derived cardiomyocytes. Lysosomal and proteasomal chemical inhibitors were used together with cell imaging and protein analysis tools in order to dissect degradation pathways associated with expressed PLN constructs. Transcriptional profiling of the cardiomyocytes transfected by wild-type or L39X mutant PLN modRNA was analysed with bulk RNA sequencing.
RESULTS
Our modRNA assay system revealed that transfected L39X mRNA was stable and actively translated in vitro but with only trace amount of protein detectable. Proteasomal inhibition of cardiomyocytes transfected with L39X mutant PLN modRNA showed a fourfold increase in protein expression levels. Additionally, RNA sequencing analysis of protein degradational pathways showed a significant distinct transcriptomic signature between wild-type and L39X mutant PLN modRNA transfected cardiomyocytes.
CONCLUSION
Our results demonstrate that the cardiomyopathic PLN null mutant L39X is rapidly, actively and specifically degraded by proteasomal pathways. Herein, and to the best of our knowledge, we report for the first time the usage of modified mRNAs to screen for and illuminate alternative molecular pathways found in genes associated with inherited cardiomyopathies.
Identifiants
pubmed: 34496741
doi: 10.1186/s10020-021-00362-8
pii: 10.1186/s10020-021-00362-8
pmc: PMC8425124
doi:
Substances chimiques
Biomarkers
0
Calcium-Binding Proteins
0
RNA, Messenger
0
phospholamban
0
Proteasome Endopeptidase Complex
EC 3.4.25.1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
102Subventions
Organisme : European Research Council
ID : AdG743225
Pays : International
Organisme : Vetenskapsrådet
ID : Dnr 541-2013-8351
Informations de copyright
© 2021. The Author(s).
Références
J Biol Chem. 1991 Sep 15;266(26):17707-12
pubmed: 1832676
Cardiovasc Drugs Ther. 2020 Dec;34(6):871-880
pubmed: 32822006
N Engl J Med. 2010 Oct 7;363(15):1397-409
pubmed: 20660394
Sci Rep. 2017 May 19;7(1):2193
pubmed: 28526819
J Physiol. 2017 Jun 15;595(12):4051-4071
pubmed: 28181243
J Clin Invest. 2013 Jan;123(1):46-52
pubmed: 23281409
Eur Heart J. 2021 Jan 7;42(2):178-188
pubmed: 33245749
Med Chem. 2016;12(2):151-61
pubmed: 26411602
J Cell Biol. 2012 Nov 12;199(4):583-8
pubmed: 23148232
Dev Cell. 2019 Feb 25;48(4):475-490.e7
pubmed: 30713072
Circulation. 2011 Jul 19;124(3):304-13
pubmed: 21709064
Cardiovasc Res. 2005 Apr 1;66(1):33-44
pubmed: 15769446
Am J Hum Genet. 2019 Apr 4;104(4):625-637
pubmed: 30879639
Gene Ther. 2020 Dec;27(12):579-590
pubmed: 32669717
Circulation. 2019 Feb 5;139(6):799-811
pubmed: 30586709
Med Chem. 2016;12(2):139-50
pubmed: 26411603
J Control Release. 2019 Sep 28;310:103-114
pubmed: 31425721
Sci Rep. 2020 Apr 27;10(1):7052
pubmed: 32341402
Exp Mol Med. 2020 Mar;52(3):400-408
pubmed: 32210357
J Clin Invest. 2003 Mar;111(6):869-76
pubmed: 12639993
Cell Death Dis. 2013 Oct 10;4:e843
pubmed: 24113177
J Biol Chem. 2008 May 2;283(18):12202-11
pubmed: 18287099
Neth Heart J. 2017 Mar;25(3):157-169
pubmed: 28102477
J Mol Cell Cardiol. 2014 Jun;71:25-31
pubmed: 24380728
J Cardiovasc Pharmacol Ther. 2017 May;22(3):273-282
pubmed: 27811197
N Engl J Med. 2021 Feb 4;384(5):403-416
pubmed: 33378609
Nat Rev Drug Discov. 2018 Apr;17(4):261-279
pubmed: 29326426
Circ Res. 2012 Jun 8;110(12):1646-60
pubmed: 22679139
Nat Protoc. 2013 Jan;8(1):162-75
pubmed: 23257984
J Mol Cell Cardiol. 2014 Jun;71:16-24
pubmed: 24239609
Nat Commun. 2019 Feb 20;10(1):871
pubmed: 30787295
Circ Res. 2017 Mar 3;120(5):781-783
pubmed: 28254803
Stem Cell Reports. 2020 Oct 13;15(4):999-1013
pubmed: 32976766
Cell Death Dis. 2016 Oct 6;7(10):e2393
pubmed: 27711080
Proc Natl Acad Sci U S A. 2015 Jun 9;112(23):7165-70
pubmed: 26040000
Ann Med. 2000 Nov;32(8):572-8
pubmed: 11127935
Cell Stem Cell. 2010 Nov 5;7(5):618-30
pubmed: 20888316
N Engl J Med. 1989 Aug 10;321(6):406-12
pubmed: 2473403
Circ Res. 2019 Sep 13;125(7):720-724
pubmed: 31513489
Cell. 2017 Jul 13;170(2):273-283.e12
pubmed: 28708997
Nat Med. 2003 May;9(5):508-9
pubmed: 12724757
Cardiovasc Drugs Ther. 2001 Sep;15(5):387-96
pubmed: 11855657
Cold Spring Harb Perspect Med. 2014 Oct 09;5(1):a014035
pubmed: 25301935
Int J Cardiol. 2019 Mar 15;279:122-125
pubmed: 30638982
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246
J Mol Med (Berl). 2008 Mar;86(3):281-9
pubmed: 17987279
EMBO Mol Med. 2019 Dec;11(12):e11115
pubmed: 31680489
Cold Spring Harb Protoc. 2012 Feb 01;2012(2):199-204
pubmed: 22301656
J Mol Cell Cardiol. 2001 May;33(5):1031-40
pubmed: 11343424